Results 91 to 100 of about 19,563 (105)

EVALUATION OF THE MINIMUM INHIBITORY CONCENTRATION OF MEROPENEM AND NEW THERAPEUTIC OPTIONS FOR SERRATIA MARCESCENS AND MORGANELLACEAE ENTEROBACTERALES WITH REDUCED SUSCEPTIBILITY TO MEROPENEM

open access: yesBrazilian Journal of Infectious Diseases
Introduction/Objective: Serratia marcescens and Enterobacterales of the Morganellaceae family are associated with infections in different sites and exhibit an expected phenotype of resistance to several antimicrobials, making therapeutic options very ...
Lívia Medeiros   +5 more
doaj   +1 more source

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections

open access: yesAntimicrobial Agents and Chemotherapy
Thirty-day mortality was similar in a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections treated with ceftazidime-avibactam or meropenem-vaborbactam.
Sara M. Karaba   +9 more
doaj   +1 more source

Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections [PDF]

open access: yes
Aims: Meropenem/vaborbactam combination is approved in adults by FDA and EMA for complicated urinary tract infections and by EMA also for other Gram-negative infections.
Tout, M   +14 more
core   +1 more source

New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Lung Transplantation: Clinical Evidence, Safety, and PK/PD Properties

open access: yesTransplant International
Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) and Pseudomonas aeruginosa are leading causes of morbidity and mortality after lung transplantation (LuTx).
Andrea Lombardi   +8 more
doaj   +1 more source

Activity of β-Lactamase Inhibitor Combinations Against Enterobacterales Isolated from Patients with Intra-Abdominal Infection from United States Medical Centres (2019–2023)

open access: yesAntibiotics
Objective: To evaluate the antimicrobial susceptibility of Enterobacterales isolated from patients with intra-abdominal infections (IAI) in United States (US) medical centres.
Helio S. Sader   +4 more
doaj   +1 more source

Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam

open access: yesAntimicrobial Agents and Chemotherapy
We report an outbreak of KPC-producing Pseudomonas aeruginosa in Spain, involving four patients and an environmental isolate recovered from a hospital sink.
Gloria Pérez-Rodríguez   +13 more
doaj   +1 more source

Activity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals

open access: yesJournal of Global Antimicrobial Resistance
Objectives: Enterobacterales isolates producing β-lactamases are widespread and threaten the use of β-lactams. This study evaluated the activity of aztreonam-avibactam and comparator antimicrobial agents against Enterobacterales isolates producing common
Lalitagauri M Deshpande   +3 more
doaj   +1 more source

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

open access: yes, 2017
Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam and the impact of bacterial efflux and permeability on its activity were determined ...
Debora Rubio-Aparicio   +6 more
core   +1 more source

Novel β-Lactam/β-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis

open access: yesAntibiotics
Background/Objectives: Carbapenem-resistant Enterobacterales (CRE) infections represent a critical global health threat with limited therapeutic options and high mortality rates.
Basim Raddam Al Shammari
doaj   +1 more source

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

open access: yesPharmaceuticals
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy